Please enable JavaScript to continue using this application.

Compare tickers

Valuation, margins, and growth side by side.

Compare $AMLX vs $INDV | Chartloom

Compare

$AMLX vs $INDV

Amylyx Pharmaceuticals Inc · Indivior Pharmaceuticals, Inc

AMLX

Amylyx Pharmaceuticals Inc

INDV

Indivior Pharmaceuticals, Inc

Compare $AMLX vs $INDV

Comparing Amylyx Pharmaceuticals Inc and Indivior Pharmaceuticals, Inc

AMLXAmylyx Pharmaceuticals Inc

INDVIndivior Pharmaceuticals, Inc

AMLXAmylyx Pharmaceuticals Inc

Market cap

$2.99B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-100.0%

YTD performance

135.1%

52W performance

88.3%

FCF yield

-4.2%

INDVIndivior Pharmaceuticals, Inc

Market cap

$4.29B

P/E (TTM)

12.37x

Forward P/E (NTM)

7.50x

Forward P/S (NTM)

3.13x

Rev growth (TTM)

13.6%

YTD performance

-0.9%

52W performance

48.9%

FCF yield

-2.5%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

AMLX

INDV

Detailed metrics comparison

AMLX

Amylyx Pharmaceuticals Inc

INDV

Indivior Pharmaceuticals, Inc

Market Cap

AMLX$2.99B

INDV$4.29B

Enterprise Value

AMLX$2.94B

INDV$4.55B

Price

AMLX$26.85

INDV$35.42

P/E Ratio

AMLXN/A

INDV12.37x

P/S Ratio

AMLX17.98x

INDV3.22x

EV/Sales

AMLX17.63x

INDV3.42x

EV/EBITDA

AMLX87.31x

INDV10.26x

P/B Ratio

AMLX14.77x

INDV422.91x

P/FCF Ratio

AMLXN/A

INDVN/A

EV/FCF

AMLX-23.17x

INDV-41.75x

PEG Ratio

AMLXN/A

INDV0.41x

Forward P/E (NTM)

AMLXN/A

INDV7.50x

Forward P/S (NTM)

AMLXN/A

INDV3.13x

Revenue (TTM)

AMLX$0

INDV$1.33B

Revenue Growth (YoY)

AMLX-100.0%

INDV13.6%

Forward Rev Growth

AMLX195.4%

INDV5.4%

Gross Margin (TTM)

AMLX82.8%

INDV82.0%

Operating Margin (TTM)

AMLX0.0%

INDV30.3%

EBITDA Margin (TTM)

AMLX0.0%

INDV33.1%

Net Margin (TTM)

AMLX0.0%

INDV26.7%

FCF Margin (TTM)

AMLXN/A

INDV-8.2%

Net Income (TTM)

AMLX$-152M

INDV$355M

FCF (TTM)

AMLX$-127M

INDV$-109M

EPS (TTM)

AMLX-$1.37

INDV$2.86

ROE (TTM)

AMLX-5292.0%

INDV159.1%

ROA (TTM)

AMLX-4853.0%

INDV28.1%

ROIC (TTM)

AMLX-5292.0%

INDV29.4%

Cash

AMLX$49M

INDV$222M

Debt

AMLX$0

INDV$487M

Net Cash/Debt

AMLX$49M

INDV$-265M

Current Ratio (TTM)

AMLX12.12x

INDV0.84x

Quick Ratio (TTM)

AMLX11.86x

INDV0.65x

Debt/Equity (TTM)

AMLX0.00x

INDV27.90x

Debt/Assets (TTM)

AMLX0.0%

INDV0.0%

Interest Coverage (TTM)

AMLXN/A

INDVN/A

Net Debt/EBITDA (TTM)

AMLX0.00x

INDV0.00x

Beta

AMLX-0.10

INDV0.49

52W Performance

AMLX88.3%

INDV48.9%

YTD Performance

AMLX135.1%

INDV-0.9%

% from 52W High

AMLX-34.7%

INDV-17.3%

% from 52W Low

AMLX147.9%

INDV50.4%

Asset Turnover (TTM)

AMLX0.50x

INDV1.06x

FCF Yield (TTM)

AMLX-4.2%

INDV-2.5%

Earnings Yield (TTM)

AMLX-5.1%

INDV8.3%

Dividend Yield (TTM)

AMLXN/A

INDVN/A

Rule of 40

AMLX-100.0

INDV5.4

EV/GP/RG

AMLXN/A

INDV1.40

Ticker research

View AMLX research View INDV research

Metric	AMLX Amylyx Pharmaceuticals Inc	INDV Indivior Pharmaceuticals, Inc
Market & Valuation
Market Cap	$2.99B	$4.29B
Enterprise Value	$2.94B	$4.55B
Price	$26.85	$35.42
P/E Ratio	N/A	12.37x
P/S Ratio	17.98x	3.22x
EV/Sales	17.63x	3.42x
EV/EBITDA	87.31x	10.26x
P/B Ratio	14.77x	422.91x
P/FCF Ratio	N/A	N/A
EV/FCF	-23.17x	-41.75x
PEG Ratio	N/A	0.41x
Forward P/E (NTM)	N/A	7.50x
Forward P/S (NTM)	N/A	3.13x
Revenue & Growth
Revenue (TTM)	$0	$1.33B
Revenue Growth (YoY)	-100.0%	13.6%
Forward Rev Growth	195.4%	5.4%
Profitability
Gross Margin (TTM)	82.8%	82.0%
Operating Margin (TTM)	0.0%	30.3%
EBITDA Margin (TTM)	0.0%	33.1%
Net Margin (TTM)	0.0%	26.7%
FCF Margin (TTM)	N/A	-8.2%
Net Income (TTM)	$-152M	$355M
FCF (TTM)	$-127M	$-109M
EPS (TTM)	-$1.37	$2.86
ROE (TTM)	-5292.0%	159.1%
ROA (TTM)	-4853.0%	28.1%
ROIC (TTM)	-5292.0%	29.4%
Financial Health
Cash	$49M	$222M
Debt	$0	$487M
Net Cash/Debt	$49M	$-265M
Current Ratio (TTM)	12.12x	0.84x
Quick Ratio (TTM)	11.86x	0.65x
Debt/Equity (TTM)	0.00x	27.90x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.10	0.49
52W Performance	88.3%	48.9%
YTD Performance	135.1%	-0.9%
% from 52W High	-34.7%	-17.3%
% from 52W Low	147.9%	50.4%
Efficiency & Yields
Asset Turnover (TTM)	0.50x	1.06x
FCF Yield (TTM)	-4.2%	-2.5%
Earnings Yield (TTM)	-5.1%	8.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-100.0	5.4
EV/GP/RG	N/A	1.40
Ticker research	View AMLX research	View INDV research

Valuation

P/E Ratio

INDV

12.37x

P/S Ratio

INDV

3.22x

AMLX

17.98x

EV/FCF

INDV

-41.75x

AMLX

-23.17x

Growth & revenue

Revenue Growth TTM

INDV

13.6%

AMLX

-100.0%

Forward Revenue Growth

AMLX

195.4%

INDV

5.4%

Profitability & performance

Gross Margin

AMLX

82.8%

INDV

82.0%

ROE

INDV

159.1%

AMLX

-5292.0%

FCF Yield %

INDV

-2.5%

AMLX

-4.2%

52-Week Performance

AMLX

88.3%

INDV

48.9%

Detailed metrics comparison

AMLX

Amylyx Pharmaceuticals Inc

INDV

Indivior Pharmaceuticals, Inc

Market Cap

AMLX$2.99B

INDV$4.29B

Enterprise Value

AMLX$2.94B

INDV$4.55B

Price

AMLX$26.85

INDV$35.42

P/E Ratio

AMLXN/A

INDV12.37x

P/S Ratio

AMLX17.98x

INDV3.22x

EV/Sales

AMLX17.63x

INDV3.42x

EV/EBITDA

AMLX87.31x

INDV10.26x

P/B Ratio

AMLX14.77x

INDV422.91x

P/FCF Ratio

AMLXN/A

INDVN/A

EV/FCF

AMLX-23.17x

INDV-41.75x

PEG Ratio

AMLXN/A

INDV0.41x

Forward P/E (NTM)

AMLXN/A

INDV7.50x

Forward P/S (NTM)

AMLXN/A

INDV3.13x

Revenue (TTM)

AMLX$0

INDV$1.33B

Revenue Growth (YoY)

AMLX-100.0%

INDV13.6%

Forward Rev Growth

AMLX195.4%

INDV5.4%

Gross Margin (TTM)

AMLX82.8%

INDV82.0%

Operating Margin (TTM)

AMLX0.0%

INDV30.3%

EBITDA Margin (TTM)

AMLX0.0%

INDV33.1%

Net Margin (TTM)

AMLX0.0%

INDV26.7%

FCF Margin (TTM)

AMLXN/A

INDV-8.2%

Net Income (TTM)

AMLX$-152M

INDV$355M

FCF (TTM)

AMLX$-127M

INDV$-109M

EPS (TTM)

AMLX-$1.37

INDV$2.86

ROE (TTM)

AMLX-5292.0%

INDV159.1%

ROA (TTM)

AMLX-4853.0%

INDV28.1%

ROIC (TTM)

AMLX-5292.0%

INDV29.4%

Cash

AMLX$49M

INDV$222M

Debt

AMLX$0

INDV$487M

Net Cash/Debt

AMLX$49M

INDV$-265M

Current Ratio (TTM)

AMLX12.12x

INDV0.84x

Quick Ratio (TTM)

AMLX11.86x

INDV0.65x

Debt/Equity (TTM)

AMLX0.00x

INDV27.90x

Debt/Assets (TTM)

AMLX0.0%

INDV0.0%

Interest Coverage (TTM)

AMLXN/A

INDVN/A

Net Debt/EBITDA (TTM)

AMLX0.00x

INDV0.00x

Beta

AMLX-0.10

INDV0.49

52W Performance

AMLX88.3%

INDV48.9%

YTD Performance

AMLX135.1%

INDV-0.9%

% from 52W High

AMLX-34.7%

INDV-17.3%

% from 52W Low

AMLX147.9%

INDV50.4%

Asset Turnover (TTM)

AMLX0.50x

INDV1.06x

FCF Yield (TTM)

AMLX-4.2%

INDV-2.5%

Earnings Yield (TTM)

AMLX-5.1%

INDV8.3%

Dividend Yield (TTM)

AMLXN/A

INDVN/A

Rule of 40

AMLX-100.0

INDV5.4

EV/GP/RG

AMLXN/A

INDV1.40

Ticker research

View AMLX research View INDV research

Metric	AMLX Amylyx Pharmaceuticals Inc	INDV Indivior Pharmaceuticals, Inc
Market & Valuation
Market Cap	$2.99B	$4.29B
Enterprise Value	$2.94B	$4.55B
Price	$26.85	$35.42
P/E Ratio	N/A	12.37x
P/S Ratio	17.98x	3.22x
EV/Sales	17.63x	3.42x
EV/EBITDA	87.31x	10.26x
P/B Ratio	14.77x	422.91x
P/FCF Ratio	N/A	N/A
EV/FCF	-23.17x	-41.75x
PEG Ratio	N/A	0.41x
Forward P/E (NTM)	N/A	7.50x
Forward P/S (NTM)	N/A	3.13x
Revenue & Growth
Revenue (TTM)	$0	$1.33B
Revenue Growth (YoY)	-100.0%	13.6%
Forward Rev Growth	195.4%	5.4%
Profitability
Gross Margin (TTM)	82.8%	82.0%
Operating Margin (TTM)	0.0%	30.3%
EBITDA Margin (TTM)	0.0%	33.1%
Net Margin (TTM)	0.0%	26.7%
FCF Margin (TTM)	N/A	-8.2%
Net Income (TTM)	$-152M	$355M
FCF (TTM)	$-127M	$-109M
EPS (TTM)	-$1.37	$2.86
ROE (TTM)	-5292.0%	159.1%
ROA (TTM)	-4853.0%	28.1%
ROIC (TTM)	-5292.0%	29.4%
Financial Health
Cash	$49M	$222M
Debt	$0	$487M
Net Cash/Debt	$49M	$-265M
Current Ratio (TTM)	12.12x	0.84x
Quick Ratio (TTM)	11.86x	0.65x
Debt/Equity (TTM)	0.00x	27.90x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.10	0.49
52W Performance	88.3%	48.9%
YTD Performance	135.1%	-0.9%
% from 52W High	-34.7%	-17.3%
% from 52W Low	147.9%	50.4%
Efficiency & Yields
Asset Turnover (TTM)	0.50x	1.06x
FCF Yield (TTM)	-4.2%	-2.5%
Earnings Yield (TTM)	-5.1%	8.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-100.0	5.4
EV/GP/RG	N/A	1.40
Ticker research	View AMLX research	View INDV research